Novo Nordisk India has entered into a strategic partnership with Emcure Pharmaceuticals to launch Poviztra®, the second brand of Wegovy® (semaglutide injection 2.4 mg), as part of efforts to widen access to its globally acclaimed anti-obesity therapy.

The deal makes Emcure the first Indian pharmaceutical company with exclusive rights to distribute and commercialise semaglutide for chronic weight management in India.

Under the arrangement, Emcure will take charge of the commercialisation, marketing, and distribution of Poviztra®, building on Novo Nordisk’s footprint to reach more pharmacies and patients, especially in smaller towns and regions beyond the multinational’s current reach.

Second brand to strengthen reach

Poviztra® will serve as a second brand of Wegovy®, which Novo Nordisk

See Full Page